Hepion Pharmaceuticals Inc
NASDAQ:HEPA
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6830
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.6627/ 12
  • Ask / Lots
    0.7150/ 49
  • Open / Previous Close
    --- / 0.6830
  • Day Range
    ---
  • 52 Week Range
    0.5525
    4.4700
  • Volume
    422

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 11, 2024

      Show headlines and story abstract

    • 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
      Companies Mentioned: HEPA

      In connection with the Proposed Transaction, Pharma Two B filed the Registration Statement with the SEC, which includes a prospectus with respect to its securities to be issued in connection with the Proposed Transaction, and a definitive proxy statement with respect to Hepion's stockholder meeting at which Hepion's stockholders will be asked to vote on the Proposed Transaction and related matters. The Registration Statement has been declared effective by the SEC and Hepion is mailing a definitive proxy statement and prospectus to its shareholders. Each of Hepion and Pharma Two B urge investors, stockholders, and other interested persons to read, when available, the Registration Statement including the proxy statement/prospectus, any amendments thereto, and any other documents filed with the SEC, before making any voting or investment decision because these documents will contain important information about the Proposed Transaction.